omniture
和铂医药(上海)有限公司 Harbour BioMed

Latest News

Nona Biosciences Successfully Develops World's First Language Model Trained on Fully Human Heavy-Chain-Only Antibodies

CAMBRIDGE, Mass., Sept. 16, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology ...

2026-09-16 18:01 1990

Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clin...

2026-09-09 19:12 2217

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the...

2026-09-08 20:17 1984

Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed...

2026-08-27 22:09 2629

Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed...

2026-08-27 22:04 5389

Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed...

2026-08-18 17:02 1908

Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed ...

2026-08-06 16:10 3073

Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2026 /PRNewswire/ -- Harbour BioMed...

2026-07-27 17:02 3458

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed...

2026-07-24 08:02 6929

Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases

Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice ® transgenic mouse ...

2026-07-23 08:55 3071

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 15, 2026 /PRNewswire/ -- Harbour BioMed...

2026-07-15 18:01 4021

Nona Biosciences Appoints Dr. Peng Wang as Chief Operating Officer to Advance Platform Capabilities and Drive Operational Excellence

CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global...

2026-07-03 09:36 4828

Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Nona Biosciences ("Nona"), a global biotechnology co...

2026-07-02 08:05 3739

Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 28, 2026 /PRNewswire/ -- Harbour BioMed...

2026-06-29 09:27 2494

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

* The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an ...

2026-06-15 08:01 6663

Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed...

2026-06-12 09:19 8848

Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed...

2026-06-11 09:52 4470

Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed...

2026-06-10 12:06 6009

First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody

* COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second m...

2026-06-09 20:23 6050
12345 ... 7